Technical Analysis for DMPI - DelMar Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.6011 -0.25% 0.00
DMPI closed down 0.25 percent on Friday, September 20, 2019, on 7 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Sep 23

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical DMPI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Narrow Range Bar Range Contraction -0.25%
NR7 Range Contraction -0.25%
NR7-2 Range Contraction -0.25%

Older signals for DMPI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
Medicine Cancer Clinical Medicine Treatment Of Cancer Oncology Chemotherapy Drug Discovery Cancer Treatments Antineoplastic Drugs Drug Development Leukemia Glioblastoma Brain Tumor Lung Cancer Brain Cancer Glioblastoma Multiforme
Is DMPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.5
52 Week Low 0.55
Average Volume 962,303
200-Day Moving Average 2.7513
50-Day Moving Average 1.0735
20-Day Moving Average 0.6431
10-Day Moving Average 0.6386
Average True Range 0.101
ADX 26.96
+DI 29.1957
-DI 19.2625
Chandelier Exit (Long, 3 ATRs ) 0.597
Chandelier Exit (Short, 3 ATRs ) 0.853
Upper Bollinger Band 0.7482
Lower Bollinger Band 0.538
Percent B (%b) 0.3
BandWidth 32.68543
MACD Line -0.1254
MACD Signal Line -0.1543
MACD Histogram 0.0289
Fundamentals Value
Market Cap 12.95 Million
Num Shares 21.6 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -0.81
Price-to-Sales 0.00
Price-to-Book 77.27
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.63
Resistance 3 (R3) 0.63 0.63 0.63
Resistance 2 (R2) 0.63 0.62 0.63 0.62
Resistance 1 (R1) 0.61 0.61 0.62 0.61 0.62
Pivot Point 0.61 0.61 0.61 0.61 0.61
Support 1 (S1) 0.59 0.60 0.60 0.59 0.58
Support 2 (S2) 0.59 0.59 0.59 0.58
Support 3 (S3) 0.57 0.59 0.58
Support 4 (S4) 0.57